Showing results (561-570 of 757) with videos related to

Sort By:
Pageof 76
Advances in Therapy|September 23, 2025
A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) CollaborationJuan José Garcia Sanchez, Marta Trapero-Bertran, Oriana Ciani, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 2, 2022
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority TrialDaniel W Coyne, Ajay K Singh, Renato D Lopes, et al.
Journal of the American College of Cardiology|May 10, 2023
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk CategoriesJaved Butler, Milton Packer, Tariq Jamal Siddiqi, et al.
Molecular Genetics and Metabolism|April 22, 2008
Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3Anouk C Vedder, Frank Breunig, Wilma E Donker-Koopman, et al.
Kidney International Reports|January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor TherapyPeter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
European Heart Journal|March 4, 2025
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Andrew Coats, et al.
JAMA Cardiology|January 3, 2024
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical TrialsNikolaus Marx, Ahmed A Kolkailah, Julio Rosenstock, et al.
Kidney International|November 12, 2020
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trialBettina J Kraus, Matthew R Weir, George L Bakris, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 4, 2010
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry RegistryChristoph Wanner, João P Oliveira, Alberto Ortiz, et al.
The Journal of Clinical Endocrinology and Metabolism|April 13, 2026
Combination Treatment for Management of Chronic Kidney Disease and Type 2 Diabetes: A Review and Practical GuidanceMai Mohsen, Tae Won Yi, Labib Faruque, et al.
Pageof 76